ERCP devices market to reach USD 2.8B by 2032

The endoscopic retrograde cholangiopancreatography (ERCP) devices market sales is expected to reach US$ 1.5 billion in 2022 and US$ 2.8 billion by 2032 as a result of an increase in cancer incidence worldwide. The market for endoscopic retrograde cholangiopancreatography (ERCP) equipment is anticipated to develop at a compound annual growth rate (CAGR) of 6.2% between 2022 and 2032, according to forecasts by FMI.

The Endoscopic Retrograde Cholangiopancreatography (ERCP) devices market is undergoing significant developments, showcasing its pivotal role in diagnostic and therapeutic procedures for pancreatic and biliary disorders. As an integral part of minimally invasive endoscopic techniques, ERCP devices enable healthcare professionals to visualize, diagnose, and treat conditions affecting the pancreas and bile ducts. Continuous advancements in technology are enhancing the precision and effectiveness of these devices, contributing to improved patient outcomes. Stakeholders in the market, including medical device manufacturers and healthcare practitioners, are actively engaged in innovations to address evolving clinical needs and enhance the efficiency of ERCP procedures.

The market for endoscopic retrograde cholangiopancreatography (ERCP) devices combines fluoroscopic imaging and luminal endoscopy for the diagnosis and treatment of pancreatobiliary system disorders. Endoscopic retrograde cholangiopancreatography (ERCP) devices use a side-view duodenoscopy that is then passed through the oesophagus and stomach into the duodenum’s latter section. Endoscopic retrograde cholangiopancreatography (ERCP) devices are primarily used to collect tissue and cell samples, as well as to treat a blocked pancreatic or bile duct.

The blockage of the ducts could be caused by non-cancerous stones in the duct or by cancer. Endoscopic retrograde cholangiopancreatography (ERCP) imaging tests are used for diagnosis or examination of the pancreatic ducts, as well as the gallbladder, liver, and pancreas. Magnetic resonance cholangiopancreatography and computed tomography machines are alternatives to endoscopic retrograde cholangiopancreatography (ERCP) devices. Endoscopic retrograde cholangiopancreatography (ERCP) devices are used for a variety of procedures such as sphincterotomy, stone removal, stent placement, dilatation, and draining bodily fluids.

Endoscopic Retrograde Cholangiopancreatography (ECRP) devices market: Drivers and restraints-
Over the years, endoscopic retrograde cholangiopancreatography (ECRP) devices have grown in popularity for cancer treatment. During the forecast period, the increasing incidence of benign liver and pancreatic tumours is expected to create appealing market opportunities for endoscopic retrograde cholangiopancreatography (ECRP) devices across regions.

Several ongoing studies for safer use and improved efficiency of these endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as rising government support for R&D, may also drive market growth for endoscopic retrograde cholangiopancreatography (ECRP) devices over the forecast period. Growing awareness of endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as an increase in availability, are expected to drive market growth for ECRP devices.

On the other hand, high endoscopic retrograde cholangiopancreatography (ECRP) device costs and side effects such as post-ERCP pancreatitis, infection, haemorrhage, and allergic reactions associated with cholangiopancreatography procedures are expected to stymie market growth for endoscopic retrograde cholangiopancreatography (ECRP) devices during the forecast period.

Endoscopic Retrograde Cholangiopancreatography (ECRP) devices market: Overview
Endoscopic retrograde cholangiopancreatography (ECRP) devices use advanced techniques and thus have a higher rate of serious complications than other endoscopic procedures. As a result, specialised equipment and training are required, and the procedure is carried out for appropriate applications. According to a review by Freeman et al, approximately 500,000 procedures are performed in the United States each year. Endoscopic retrograde cholangiopancreatography (ECRP) devices are frequently used in hospital settings where patients with pancreatic or gallstone disease are admitted.

Tissue sampling or biliary or pancreatic ductal system disease treatment, obstructive jaundice, pancreatitis of unknown cause, suspicion for pancreatic cancer, nasobiliary drainage, manometry for sphincter of Oddi, biliary stenting for leakage and strictures, balloon dilation of ductal strictures and duodenal papill, and drainage of pancreatic pseudocysts are

Endoscopic Retrograde Cholangiopancreatography (ECRP) devices market: Region-wise outlook
The market for endoscopic retrograde cholangiopancreatography (ECRP) devices in North America is expected to grow significantly as a result of increased diagnostic imaging-related research and improved research and development for advanced and safe endoscopic retrograde cholangiopancreatography (ECRP) devices. During the forecast period, improved healthcare infrastructure and expenditure are expected to drive the Europe market for endoscopic retrograde cholangiopancreatography (ECRP) devices.

Growing cholangiopancreatography procedure awareness in China, India, and Japan is expected to fuel the Asia-Pacific market for endoscopic retrograde cholangiopancreatography (ECRP) devices. The constant increase in the number of endoscopic retrograde cholangiopancreatography (ECRP) device manufacturers is expected to drive demand for ECRP devices during the forecast period. Future Market Insights